Literature DB >> 7955522

Pneumocystis carinii-induced activation of the respiratory burst in human monocytes and macrophages.

A L Laursen1, B Møller, J Rungby, C M Petersen, P L Andersen.   

Abstract

Human monocytes and monocyte-derived macrophages were studied for their ability to phagocytose Pneumocystis carinii and produce superoxide (O2-) during the process. One x 10(6) freshly isolated monocytes, incubated with 0.1-3.75 x 10(6) P. carinii cysts, increased O2- production in a dose-related way. Antibodies were essential for the process since opsonized, but not unopsonized, pneumocysts induced O2- production significantly above the response obtained by lung tissue from rats (10.7 and 4.9 versus 3.0 fmol/cell per 90 min). The difference between pneumocysts opsonized in untreated versus complement-depleted serum was not significant (10.7 versus 12.6 fmol/cell per 90 min). Monocyte-derived macrophages also activated the respiratory burst when stimulated with pneumocysts, and this effect could be significantly increased, from 4.2 to 8.8 fmol/cell per 90 min, when cells were primed with interferon-gamma (IFN-gamma). Cells primed with IL-3 also increased O2- production, though to a lesser extent. In contrast, granulocyte-macrophage colony-stimulating factor (GM-CSF) had only a small effect on the respiratory burst in cells stimulated with P. carinii. Priming with IFN-gamma increased the rate of phagocytosis in macrophages. After incubation for 90 min or more, however, the percentage of cells with phagocytic vacuoles was only slightly higher in IFN-gamma-primed cells. When examined by electron microscopy (EM), most vacuoles contained partially or totally degraded pneumocysts. In conclusion, we have demonstrated the ability of monocytes and monocyte-derived macrophages to ingest and degrade pneumocysts, activating the respiratory burst during the process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955522      PMCID: PMC1534412          DOI: 10.1111/j.1365-2249.1994.tb06125.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Killing of Histoplasma capsulatum by gamma-interferon-activated human monocyte-derived macrophages: evidence for a superoxide anion-dependent mechanism.

Authors:  E Brummer; N Kurita; S Yoshida; K Nishimura; M Miyaji
Journal:  J Med Microbiol       Date:  1991-07       Impact factor: 2.472

2.  Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex.

Authors:  L E Bermudez; L S Young
Journal:  J Leukoc Biol       Date:  1990-07       Impact factor: 4.962

3.  IFN-gamma and LPS overcome glucocorticoid inhibition of priming for superoxide release in human monocytes. Evidence that secretion of IL-1 and tumor necrosis factor-alpha is not essential for monocyte priming.

Authors:  S J Szefler; C E Norton; B Ball; J M Gross; Y Aida; M J Pabst
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

4.  Modulation of Mycobacterium avium growth in murine macrophages: reversal of unresponsiveness to interferon-gamma by indomethacin or interleukin-4.

Authors:  M Denis; E O Gregg
Journal:  J Leukoc Biol       Date:  1991-01       Impact factor: 4.962

5.  Interferon-gamma concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1.

Authors:  D Fuchs; A Hausen; G Reibnegger; E R Werner; G Werner-Felmayer; M P Dierich; H Wachter
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

6.  Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models.

Authors:  F Gigliotti; W T Hughes
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

7.  Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates.

Authors:  J A Kovacs; J L Halpern; B Lundgren; J C Swan; J E Parrillo; H Masur
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

8.  Patterns of interferon-gamma production by peripheral blood mononuclear cells from patients with human immunodeficiency virus infection.

Authors:  M A Nokta; R B Pollard
Journal:  J Interferon Res       Date:  1990-04

9.  Local antibodies against Pneumocystis carinii in bronchoalveolar lavage fluid.

Authors:  A L Laursen; B N Jensen; P L Andersen
Journal:  Eur Respir J       Date:  1994-04       Impact factor: 16.671

10.  The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group.

Authors:  J Phair; A Muñoz; R Detels; R Kaslow; C Rinaldo; A Saah
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more
  5 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.

Authors:  Jesse Wells; Constantine G Haidaris; Terry W Wright; Francis Gigliotti
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii.

Authors:  A L Laursen; S C Mogensen; H M Andersen; P L Andersen; S Ellermann-Eriksen
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

4.  Defective nitric oxide production by alveolar macrophages during Pneumocystis pneumonia.

Authors:  Mark E Lasbury; Chung-Ping Liao; Chadi A Hage; Pamela J Durant; Dennis Tschang; Shao-Hung Wang; Chen Zhang; Chao-Hung Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2010-06-17       Impact factor: 6.914

5.  Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor.

Authors:  Chad Steele; Luis Marrero; Steve Swain; Allen G Harmsen; Mingquan Zheng; Gordon D Brown; Siamon Gordon; Judd E Shellito; Jay K Kolls
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.